Guggenheim raised the firm’s price target on Vera Therapeutics (VERA) to $65 from $61 and keeps a Buy rating on the shares after the company reported “overwhelmingly positive” topline results from its pivotal Phase 3 ORIGIN 3 trial in IgA nephropathy. Following the data, the firm is increasing its view of the probability of success for atacicept to 90% from 85%, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics price target raised to $65 from $55 at Scotiabank
- Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment
- Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment
- H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data
- Vera Therapeutics Announces Positive Phase 3 Trial Results